Colorectal carcinoma (CRC) · line 2 · FOLFIRI + Bevacizumab (or ± cetuximab if RAS-WT left-sided)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-FOLFIRI-BEV |
| ID | IND-CRC-METASTATIC-2L-FOLFIRI-BEV |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CRC |
| Sources | SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track 2L mCRC cytotoxic switch + biologic continuation. MSI-H patients remain on pembrolizumab past 1L (separate continuation Indication, future). BRAF V600E patients may instead switch to encorafenib + cetuximab (existing IND-CRC-METASTATIC-2L-BRAF-BEACON) — distinct molecular track.
Used By
Algorithms
ALGO-CRC-METASTATIC-2L- ALGO-CRC-METASTATIC-2L
Indication
IND-CRC-METASTATIC-MAINT-FOLFIRI-BEV- IND-CRC-METASTATIC-MAINT-FOLFIRI-BEV